|
JX-594 is an oncolytic virus (also known as Pexa-Vec〔) developed by Jennerex and partners: Transgene S.A.; Lee's Pharmaceutical Holdings Ltd.; and Green Cross Corp. Pexa-Vec is designed to target and destroy cancer cells.〔(Un virus contre le cancer ) 25 March 2012, Radio Canada 〕 JX-594 is a vaccinia poxvirus engineered by addition of the GM-CSF gene and deletion of the thymidine kinase gene which limits viral replication to cells with high levels of thymidine kinase, typically seen in cancer cells with a mutated RAS or p53 gene. The virus kills them by lysis and also expresses GM-CSF which may help initiate an anti-tumour immune response.〔(【引用サイトリンク】url=http://www.cancer.gov/drugdictionary?CdrID=579292 )〕 It has orphan drug designation from US FDA and EUMA for the treatment of hepatocellular carcinoma (HCC).〔(Jennerex Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC) )〕 ==Clinical trials== Two Phase I trials have reported results and a phase II trial for primary liver cancer, alone and in combination with sorafenib is starting.〔 JX-594〔http://www.voanews.com/english/news/health/Cancer-Fighting-Engineered-Virus-Makes-Medical-History-128899673.html September 01, 2011 Voice of America〕 Phase I results in 23 patients had encouraging results in 6 of 8 high dosed patients. Early results, in Nov 2011, from a small (30 patient) phase II trial in advanced hepatocellular carcinoma (HCC) showed an increased median overall survival of 13.8 months compared 6.7 months for a lower dose (p=0.029). 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「JX-594」の詳細全文を読む スポンサード リンク
|